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Thefir~t realizc:tio~ that cervical cancer was a sexually transmitted disease was originally 
made in the. mId-nineteenth cen~ury?y the Italian chiefphysician of a Verona hospital and 
an instructor at the Unzverszty of Padua, Domenico Antonio Rigoni-Stern. 
In his presentation to the Surgeons' Subgroup of the N Congress 
of the Italian Scientists delivered on 23 September 1842, Rigori-
Stem reported that in his review of the death registries of the 
town and suburbs of Verona over a period covering 80 years 
[1760 - 1839], cancer of the cervix of the uterus was noted to 
be rare in nuns and unmarried women, but widespread in 
housewives, suggesting a sexuallink with the malignancy. As 
usually happens with a landmark observation, Rigoni-Stem's 
observations were completely ignored for the next hundred 
years. Interest in the aetiology and epidemiology of cervical 
cancer was revived during the 1940s, when a number of studies 
confirmed Rigoni-Stem's fmdings and the general consensus 
accepted that cervical neoplasia had the characteristics of a 
venereal transmitted disease. The true causative agent was 
however only identified in 1976. This cancer appears to be 
caused by several types of the hmnan papillomavirus (HPV), 
partIcularly the subtypes HPV 16, 18,31 and 45; though a 
number of other subtypes account for other occasional cases 
(Figure 1). This virus is introduced into the genital tract during 
sexual but not necessarily penetrative intercourse; it then resides 
there causing gradual changes in the cervical epithelium that 
progress from early cellular changes, to epithelial thickening, 
to precancerous states and on to full-blown cancer.l 
Figure 1. Cervical Cancer attributed to the most frequent HP V 
types 
Celvical cancer in the world is the fifth most deadly cancer in 
women; affecting about 1 per 123 women per year and killing 
about 9 women per 100,000 per year. It is estimated that there 
are ~t anyone time about 473,000 women affected by the cervical 
mahgnancy; more than half will succumb to the disease. The 
incidence rates of cervical cancer in various populations and 
communities vary in accordance to the sexual practices of that 
community,.bein~ higher in more promiscuous societies. The 
mCldence of cervical cancer reported in Europe and the Eastem 
Mediterranean lands varies from the high 27.3 per 100,000 
women in Serbia & Montenegro to the low 2 per 100000 women 
in the Syrian Arab Republic. The rate in the Malte~e Islands 
was reported at 4.8 per 100,000 women, placing the Maltese 
population in the ninth place ofthe European-Middle East low 
lisk chart (Figure 2). It is telling that except for Finland, the 
eight countnes who reported lower rates include populations 
from the Syrian Arab Republic, Iraq, Qatar, Jordan, Israel Turkey 
and Saudi Arabia.2 ' 
The advent ofthe sexual revolution in Europe experienced 
during the "swinging sixties" - delayed in Malta to the 1980s 
because of the previously strong Roman Catholic moral influence 
- should have led to an increase in incidence rates in most 
sexually progressive communities. This rise in incidence rates 
has been observed but has not been as dramatic as one would 
have expected because of the contempormy introduction of 
effective screening programmes. Cervical cancer and 
p~ecanc?rous lesions are relatively easy to look out for by 
vlsuahzmg the cervIX and sampling the cells from the organ. 
The national service of population screening for cervical 
carcinoma was introduced in the govemment hospitals in 1977 
and expanded to the specialist community health centres or 
polyclinics in 1982. This was complimented by the service 
offered in the private health sector. The programme however 
w~ and remains an opportunistic one whereby it is left to the 
mdlVldual woman to seek screening. Many women fail to get 
thel!lselves screened or do not screen themselves regularly. The 
NatIOnal Health information Study conducted in 2002 among 
a randonuzed sample of the Maltese population has shown that 
only 45. I % of women interviewed reported having a smear test 
in the three years prior to the survey; 41.1 % reported never 
having a smear test done and 13.8% reported that the most recent 
smear was performed more than three years before.3 The last 
two decades in Malta have seen a fall in the incidence of cervical 
cancer but a significant rise in the number of premalignant 
cervi?allesion and HPV-infections. This observation suggests 
that, m spite of the rather opportunistic screening programme 
m place on the Islands, the large majority of potentially malignant 
cases are being identified and treated early before they become 
fully malignant. 
The cervical smear sampling technique was invented hy 
GeorglOs Papanokolaou in 1928 originally intended to 
detect cyclical hormonal changes in the vaginal cells and 
later developed into a cancer screening test in 1941. The 
test has changed very little since its invention; though the 
last decade has seen the development of liquid-based cell 
thm-layer technology which makes interpretation of the 
smear less susceptible to false results. The test remains 
an effective, widely used method for early detection of 
cervical cancer and pre-cancer. There is no definite 
screening prot<?col, since this varies from one country to 
another dependmg on the health services facilities available 
in each individual countJy. Countries with a comprehensive 
health .service, like the United Kingdom, propose a 
screenmg protocol based on a balance of clinical risks and 
cost concerns with the aim of covering a wide section of 
the population with the least cos1. Other countries, often 
those whose national health service is not comprehensive, 
recommend more frequent screening. The American 
guidelines mainly base the recommendations on clinical 
risk status rather than on cost concerns. 
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Figure 2. Incidence Rates of Cervical cancer in the European-
Middle East Region in 2002 (Source: Globocan 2002) 
Women with extremely low risk status - virginal women, 
after hysterectomy with removal of the cervix, or those aged 
over 65 years who have had at least 10 nonnal smears - can 
opt out from perfonning regular cervical smears. These 
extremely low risk women however can still develop different 
relatively rare fonns of cervical cancer which have no 
relationship to sexual activity. 
Those considered to be low risk women - women 
with less than three sexual lifetime partners, no history 
of sexually transmitted disease, and onset of sexual 
activity after 20 years of age - are advised to commence 
cervical cancer screening at least three years after the 
first sexual experience, followed up by annual smears 
until the age of 30 years, and subsequently 2-3 yearly 
until the age of 65 years. Those women who arc known 
to be at high risk of developing cervical cancer -
women with more than three lifetime sexual partners, 
an early sexual experience, a history of some form of 
sexually transmitted disease, and a history of an 
abnormal cervical smear in the past - should opt for 
an initial twice yearly screening followed by annual 
testin~ until there are three consecutive normal results 
after which they should opt for 2-3 yearly screening 
until the age of 65 years, provided subsequent smears 
remain normal. 
Cervical screening alone cannot be considered 
sufficient for diagnosis since false positive results can 
occur with the crude simple screening test. An abnormal 
cervical smear result is usually followed by a more 
detailed examination using a colposcope. This 
instrument is basically a 'magnifying glass' that allows 
the clinician to examine the cervix under magnification 
to identify and biopsy any sites which appear possibly 
abnormal. A colposcopic service enabling the better 
investigation and management of premalignant lesions 
was first introduced in Malta in 1987. The biopsy can 
then give a more definite diagnosis upon which a 
clinical decision regarding management can be made. 
Depending on the severity of the condition, the 
management can range from regular follow-ups to 
local destruction of the lesion, to excision of the cervix 
to an extensive hysterectomy. 
All these facilities have helped reduce the mortality 
ot cervIcal cancer III the Maltese Islands from the level 
of4.8 per 100,000 women in the early 1960s to 3 in 
the early 2000's. This reduction has occurred in spite 
of the increase in sexual activity which has occurred 
in the last decades. 4 A recent survey has shown that 
only 20% of Maltese individuals reported having one 
sexual partner, 23% reported having had more than 
10 partners . The first sexual encounter on average 
occurs at about 19 years of age; however 22% of girls 
and 13% of boys had their first sexual encounter by 
15 years of age. 5 
The fight against this destructive disease has however 
been limited in the sense that attempts have been done 
to identify and treat premalignant conditions early. The 
screening methods in place therefore help reduce the 
incidence and hence mortality of cervical cancer; but 
they do not help reduce the rising incidence of cervical 
premalignant conditions brought on by an increasing 
promiscuous lifestyle. They do not offer any prevention 
against the infection. The breakthrough in prevention 
has come in recent years by the introduction of specific 
vaccines to protect against the two subtypes of the 
HPV most responsible for the development of cervical 
cancer. Two vaccines have been introduced locally by 
different companies. Both protect against subtypes 
HPV 16 and 18 that account for over 70% of cervical 
cancer cases. They also seem to have crossover cover 
against other HPV subtypes. Obviously, protective 
cover is only effective provided the woman has not 
been previously infected. Hence it is recommended 
that ideally the vaccine is administered to females 
before they become sexually active starting by 
vaccinating children aged 10 years . Because of the 
rarer forms of HPV subtypes that cause cervical lesions 
and which are not covered by the vaccine, the 
administration of the vaccine does not exclude the need 
for continuing with a scheme of cervical screening. 
One would hope that the Maltese health authorities 
will be bold enough to emulate their counterparts in 
other European countries and introduce the vaccine in 
the vaccination schedule currently in force. The 
economic costs of vaccination far outplay the economic, 
psychological and physical costs of treating cervical 
premalignant and malignant lesions. 8J 
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